You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • OP0167 A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis

Article metrics

Article menu
Download PDFPDF
Scientific Abstracts
Oral Presentations
Abstract Session: Spondyloarthritis – clinical aspects and treatment
OP0167 A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 20145802
Mar 20141500
Apr 2014701
May 2014801
Jun 2014701
Jul 2014300
Aug 2014700
Sep 2014800
Oct 2014701
Nov 2014900
Dec 2014201
Jan 20151100
Feb 20151700
Mar 2015700
Apr 2015500
May 2015301
Jun 2015300
Jul 20151202
Aug 20151801
Sep 20151500
Oct 2015600
Nov 20151000
Dec 20151201
Jan 20161103
Feb 20161301
Mar 201634053
Apr 20161302
May 20161401
Jun 2016801
Jul 2016800
Aug 2016800
Sep 20161300
Oct 2016601
Nov 2016500
Dec 2016400
Jan 20171408
Feb 20171101
Mar 20171202
Apr 2017602
May 20171301
Jun 20171900
Jul 20171200
Aug 20171600
Sep 20171200
Oct 2017600
Nov 2017200
Dec 20172801
Jan 20182200
Feb 2018400
Mar 20181600
Apr 2018600
May 20181000
Jun 20181000
Jul 20181601
Aug 20181001
Sep 20185002
Oct 20181201
Nov 20181200
Feb 2019500
Apr 2019400
May 2019200
Jul 2019900
Aug 2019900
Sep 2019200
Oct 2019200
Nov 20191400
Dec 20191201
Jan 2020401
Feb 2020600
Mar 2020200
Apr 2020200
May 2020800
Jun 2020900
Jul 2020600
Aug 2020500
Sep 20201700
Oct 2020901
Nov 2020400
Dec 2020200
Jan 2021400
Feb 2021400
Mar 2021201
Apr 2021400
May 2021700
Sep 2021001
Oct 2021800
Nov 2021401
Dec 2021600
Jan 2022400
Feb 2022200
Mar 20222400
Apr 2022200
May 20221400
Jun 2022200
Jul 20222800
Aug 20221400
Sep 2022600
Oct 2022200
Nov 2022600
Dec 2022800
Jan 2023400
Feb 2023800
Mar 2023200
May 2023400
Jun 2023200
Jul 2023200
Aug 2023800
Sep 2023600
Nov 2023400
Dec 20231200
Jan 2024200
Feb 2024200
Mar 20241200
Total10580100